Symetryx Corporation Acquires 20% Stock In Neubase; Urges Board To Consider A $1 Dividend
Portfolio Pulse from Happy Mohamed
Symetryx Corporation has acquired 20% of the common stock in Neubase Therapeutics Inc. (NASDAQ:NBSE) and is urging the Board to issue a $1 per share dividend. Symetryx believes that Neubase's cash position makes it an attractive merger candidate and that a dividend would not make the company less attractive. Symetryx intends to engage with Neubase's management to maximize shareholder value and is open to all options, including a merger, acquisition, special dividend, or a winding down of the company.
September 06, 2023 | 2:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Symetryx's acquisition of 20% of Neubase and its push for a $1 per share dividend could potentially increase the value of Neubase's stock in the short term. The possibility of a merger or acquisition also adds to the attractiveness of the stock.
Symetryx's acquisition of a significant stake in Neubase and its push for a dividend could make the stock more attractive to investors, potentially driving up the price. Additionally, the mention of a possible merger or acquisition could also increase investor interest in the stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100